Sales of MSD in Korea exceeded 500 billion won

Sales increased 12% last year to 541.9 billion won, turning operating profit surplus

Keytruda recorded 200 billion won in single sales

Fast recovery to before spin off

MSD Korea surpassed 500 billion won in sales last year.

 

Keytruda's effect increased 1% year-on-year.

 

Analysts say that it will be able to quickly recover its past sales of 800 billion won before Organon's spin-off.

 

According to MSD audit report, the company recorded 541.9 billion won in sales last year.

 

The figure is up 11.8% from the previous year's 486.8 billion won.

 

During the same period, operating profit shifted from a deficit of 5.8 billion won to a surplus of 58 billion won.

 

Sales of Keytruda, an immuno-cancer drug of MSD Korea, are evaluated to have been good.

 

Keytruda's sales were not specified, but according to pharmaceutical research firm IQVIA, Keytruda surpassed 200 billion won in annual sales for the first time last year.

 

The figure rose 28.5% to 2.1 billion won from the previous year's 155.7 billion won.

 

The growth of Gardasil 9 and others also contributed to the expansion of sales.

 

Based on IQVIA, Gardasil 9 recorded 72.6 billion won last year, up 70.9% from 42.5 billion won a year earlier.

 

Another representative item of MSD Korea, the Januvia, reached 171 billion won in outpatient prescriptions last year.

 

The expansion of MSD's performance is expected to continue in the future.

 

This is because Keytruda's indication continues to expand, and from this year, it will be paid in the primary treatment of non-small cell lung cancer and the secondary treatment of Hodgkin's lymphoma.

 

In fact, even when it was first listed in August 2017, Keytruda's sales rose vertically from 10 billion won to 100 billion won.

 

At this rate, it is expected that the scale before the organon spin-off will be restored within a few years.

 

According to an audit report by MSD Korea two years ago, when the obligation to disclose audit reports of limited companies was implemented, the sales of all companies of Organon spin off are estimated to be about 800 billion won.

 

In the calculation of discontinued business profit and loss due to the division, the sales of organon products in the sales of organon products amounted to 326.8 billion won as of 2019.

 

As of 2019, product sales of MSD accounted for 98% of total sales, and product sales are total sales.

 

At that time, MSD's total sales amounted to 471.6 billion won.

 

Operating profit turned into a surplus last year as other sales increased and management costs due to spin-off decreased.

 

MSD Korea lost 18.4 billion won in 2019 and 5.8 billion won in 2020.

 

Last year, other sales rose 42.8% year-on-year to 15.8 billion won, while sales and administrative costs fell 2.9% to 97.2 billion won.

 

MSD Korea said, "Representative items such as Keytruda, Gardasil 9, and Januvia have driven sales growth, and we invested about 74.6 billion won in clinical research last year, up 33% from the previous year, which accounts for 13% of total sales."